A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients
NCT ID: NCT06021041
Last Updated: 2023-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
900 participants
OBSERVATIONAL
2018-01-13
2024-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Retrospective Study of Treatment Patterns and Clinical Outcomes in Patients With Central Nervous System Tuberculosis
NCT06011915
Tuberculosis in China
NCT01071603
Multi-Drug Resistant Tuberculosis in Korea
NCT00341601
Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China
NCT04434976
Biomarkers for Therapy Response in Drug-resistant Tuberculosis
NCT02597621
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Damaged lung ≥ 1 lobe
2. Chest CT shows lesions in ≥3 lung lobes
3. Hematogenous disseminated pulmonary tuberculosis
4. caseous pneumonia
5. bronchial tuberculosis
6. Multiple hilar or mediastinal lymph node enlargement in primary pulmonary tuberculosis
7. Rifampicin-resistant, multidrug-resistant, polydrug-resistant or pan-drug-resistant tuberculosis
8. Combined more than 2 cavities over 8mm
9. Tuberculous massive hemoptysis
10. Pulmonary tuberculosis complicated with acute infection (including multidrug-resistant bacterial infection, fungal infection or multiple infection)
11. Combined with extrapulmonary tuberculosis
* Intracranial tuberculosis, spinal cord and/or meningeal tuberculosis
* Pleural effusion, pericardial effusion
* Empyema or empyema, hemopneumothorax, tracheobronchopleural fistula and severe infection.
* Heart failure caused by cardiac tamponade or constrictive pericarditis
* Multiple sites of lymphatic tuberculosis or surgery is necessary
* Cervical lymphatic tuberculosis
* Mediastinal lymphatic tuberculosis
* Abdominal or retroperitoneal lymph node tuberculosis
* Abdominal tuberculosis, tuberculous peritonitis (ascites or multiple serous cavities)
* Intestinal tuberculosis causes complete or incomplete intestinal root obstruction or perforation or massive bleeding or severe abdominal infection
* Gastrointestinal hemorrhage caused by tuberculosis of the digestive system, etc.
* Musculoskeletal tuberculosis
* Spinal (cervical, thoracic, lumbar, sacral) tuberculosis
* Bones in other parts
* Merge surrounding abscess
* Urinary or renal tuberculosis
* Renal failure or damaged blood vessels caused by renal tuberculosis
* Ureteral stenosis or blockage caused by urinary tuberculosis
* Adrenal tuberculosis in hypoadrenal insufficiency
* Liver tuberculosis
2. Age and gender are not limited.
Exclusion Criteria
* Patients judged by the investigator to be unsuitable for inclusion in this protocol.
* The discharge diagnosis was central nervous system tuberculosis, or tuberculous meningitis, or tuberculous cerebrospinal meningitis, or tuberculous meningoencephalitis, or tuberculous encephalitis, or tuberculous brain abscess, or spinal tuberculosis, or tuberculous Hydrocephalus, and is currently participating in other clinical studies.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qin Ning
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Wuhan Pulmonary Hospital(Wuhan Institute for Tuberculosis Control)
Hubei, Wuhan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RETUBO-S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.